If you have the same number of cards in your hand as your opponent, this attack does 80 more damage.
Chilling Reign was released in 2021. Chilling Reign is grouped under the Sword & Shield era.
The checklist contains 233 cards, placing it in a large expansion range. As of 2026, the set is 5 years old and sits in a modern-era collecting window.
Grapploct (#92) is one of the Rare Holo prints in this expansion.
In 2021, Chilling Reign introduced this print of Grapploct. The printed flavor text states: "Searching for an opponent to test its skills against, it emerges onto land.
Once the battle is over, it returns to the sea." Its card type is Pokémon. The rarity label is Rare Holo.
Printed HP is 140. Energy typing is Fighting.
This gives collectors a clear identity footprint for the print. This card evolves from Clobbopus.
Current market pricing for Grapploct (Chilling Reign) sits near $0.22. Week-over-week change is limited (0.0%), indicating short-term stability.
Current value is elevated versus the 30-day mean ($0.21), by 5.9%. The 90-day window shows a floor near $0.15 and a peak around $0.22 (32% total spread), which maps to moderate-volatility movement.
Rarity classification for this copy is Rare Holo.
Grapploct sits within a broader pool of Grapploct variants that can be compared by set, rarity, and price. Comparable entries in this snapshot: 6 cards, 6 distinct sets.
In this sample, pricing ranges between $0.08 and $1.59 (1888% total span). Relative to the alternative average ($0.37), this card is -41%.
Notable alternatives include Grapploct #153 (Fusion Strike) at $0.11, Grapploct #SV073 (Shining Fates Shiny Vault) at $1.59, Grapploct #101 (Vivid Voltage) at $0.13, and Grapploct #113 (Sword & Shield) at $0.20.
Current valuation lens: We observe a 0.0% shift this week, which points toward price consolidation rather than immediate volatility. With a 32% 90-day spread ($0.15-$0.22), this card currently tracks as moderate-volatility.
Versus the 30-day average ($0.21), the card is trading 5.9% higher. Top-grade copies show substantial separation from raw: PSA 10 is pricing +29445% above the current raw benchmark.
PSA 9 is currently around $10.00, while PSA 10 is $65.00.
